Cargando…
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide
In myelodysplastic syndromes with a partial deletion of the long arm of chromosome 5, del(5q), lenalidomide is believed to reverse anergic T-cell immunity in the bone marrow resulting in suppression of the del(5q) clone. In this study we used next-generation sequencing of immunoglobulin heavy chain...
Autores principales: | Mährle, Thorben, Akyüz, Nuray, Fuchs, Pim, Bonzanni, Nicola, Simnica, Donjete, Germing, Ulrich, Asemissen, Anne Marie, Jann, Johann Christoph, Nolte, Florian, Hofmann, Wolf-Karsten, Nowak, Daniel, Binder, Mascha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601099/ https://www.ncbi.nlm.nih.gov/pubmed/30655375 http://dx.doi.org/10.3324/haematol.2018.208223 |
Ejemplares similares
-
High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias
por: Simnica, Donjete, et al.
Publicado: (2019) -
Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors
por: Simnica, Donjete, et al.
Publicado: (2020) -
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
por: Hecht, Anna, et al.
Publicado: (2021) -
Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007) -
Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21(R110) chronic lymphocytic leukemia
por: Paschold, Lisa, et al.
Publicado: (2022)